Regeneron Pharmaceuticals, Inc. logo REGN - Regeneron Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 34
HOLD 15
SELL 0
STRONG
SELL 0
| PRICE TARGET: $823.11 DETAILS
HIGH: $995.00
LOW: $641.00
MEDIAN: $839.50
CONSENSUS: $823.11
UPSIDE: 23.87%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 80% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Moderate
Trading 28.5% below fair value
Current Price $664.52
Bear Case $636.28 4.2% downside ($636.28 - $664.52) / $664.52 = -4.2% 8% stage 1 growth, 11% discount
Fair Value $930.01 40.0% upside ($930.01 - $664.52) / $664.52 = 40.0% 14% stage 1 growth, 11% discount
Bull Case $1,246.55 87.6% upside ($1,246.55 - $664.52) / $664.52 = 87.6% 18% stage 1 growth, 11% discount

Adjust Assumptions

13.7%
11.0%
3.0%

Key Value Driver

FCF growth rate (14% base case)

Terminal Value % of EV 42%
Implied Market Multiple 18.8x
Market is pricing in (growth) 8.1% vs our 13.7% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $823.11 from 49 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $930.01 per share.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions